Ensign Peak Advisors
AMLX icon

Ensign Peak Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ensign Peak Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.49M Buy
+305,441
New +$4.72M 0.01% 550

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ensign Peak Advisors's AMLX Position: Q2 2026 in Review

Ensign Peak Advisors opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 305,441 shares worth $5.49M. The stake represents 0.01% of the portfolio and ranks #550 among its holdings.

206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Ensign Peak Advisors held 305,441 shares of Amylyx Pharmaceuticals worth $5.49M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Ensign Peak Advisors position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #550 holding.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.